Jeffrey Zonder, MD

Jeffery Zonder, MD, is the leader of the Multiple Myeloma Sub-Committee at Barbara Ann Karmanos Cancer Institute and a professor of medicine in the Department of Hematology and Oncology at Wayne State University School of Medicine.

Articles

CTCL Today: Remaining Unmet Needs in CTCL

July 25th 2025

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

When to Consider Allogeneic Transplant in CTCL & Clinical Pearls for Community Providers

July 18th 2025

Panelists discuss how stem cell transplantation is considered primarily for younger patients or aggressive CTCL variants, balancing timing, remission status, and potential risks, while also emphasizing the value of early referral and specialized guidance for advanced disease.

Clinical Perspectives: When to Revisit a Prior Therapies in Mycosis Fungoides and Sézary Syndrome

July 18th 2025

Panelists discuss how decisions about reintroducing previous therapies for CTCL are based on prior tolerance, current disease state, and the reason for stopping treatment, with flexibility to recycle effective agents when appropriate.

Monitoring Mogamulizuma: Managing and Differentiating Drug vs. Disease-Related Rash

July 11th 2025

Panelists discuss how to differentiate Mogamulizumab-associated rash from CTCL using clinical clues, biopsy findings, and molecular studies, and how treatment may be modified based on rash severity and characteristics.

Personalizing Care: Treatment Decisions in Sézary Syndrome

July 11th 2025

Panelists discuss how to sequence and personalize therapy for Sézary syndrome, with mogamulizumab often used as first-line treatment due to potential for durable remission, followed by HDAC inhibitors, photopheresis, or alemtuzumab depending on disease progression and transplant planning.

Expert Perspectives: Combination Therapies in Advanced-Stage MF

July 2nd 2025

Panelists discuss how to integrate skin-directed therapies with systemic treatments for CTCL, emphasizing individualized strategies based on disease compartment, cautious layering of treatments, management of bacterial colonization (especially Staphylococcus aureus), and use of adjunctive measures, such as bleach baths, for optimizing skin health.

Treatment Challenges in Advanced Mycosis Fungoides: High Blood Burden or Nodal Disease

July 2nd 2025

Panelists discuss how to manage advanced-stage mycosis fungoides with nodal or visceral involvement by adapting treatments typically used for peripheral T-cell lymphoma, including single-agent chemotherapy and HDAC inhibitors, while accounting for long-term toxicities and unique dose considerations due to patient fragility and tumor biology.

Strategic Sequencing in Advanced Mycosis Fungoides: Choosing Between Immunomodulatory, HDAC, and Targeted Therapies

June 25th 2025

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies—such as HDAC inhibitors and immune checkpoint inhibitors— while emphasizing the importance of managing expectations and monitoring adverse effects.

Advanced-Stage Mycosis Fungoides: Navigating Treatment Decisions Amid a Complex Therapeutic Landscape

June 25th 2025

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Monitoring Response in Early-Stage Mycosis Fungoides & Importance of Patient Education

June 18th 2025

Panelists discuss how careful patient monitoring, education, and expectation management are essential in evaluating the effectiveness of skin-directed therapies, emphasizing routine assessments, treatment adherence, and the need for patience due to varying response times.

Other Treatment Strategies in Early-Stage Mycosis Fungoides: TSEBT, Localized Radiotherapy, Phototherapy and Combination Approach

June 18th 2025

Panelists discuss how electron therapy—both spot and total skin electron beam—is used to manage extensive or refractory skin involvement and palliate symptoms in patients with CTCL.

Collaborating With Dermatologists: Coordinating Skin-Directed Therapy and Follow-Up in CTCL

June 10th 2025

Panelists discuss how multidisciplinary collaboration between dermatologists and oncologists helps optimize personalized treatment plans by integrating skin-directed and systemic therapies.

Managing Early-Stage Mycosis Fungoides: Treatment Goals and Topical Therapy Selection

June 10th 2025

Panelists discuss how therapeutic goals for early-stage CTCL focus on symptom control with skin-directed therapies, avoiding systemic chemotherapy due to long-term toxicity and poor outcomes.

Understanding CTCL Staging: From Limited Mycosis Fungoides to Advanced Disease

June 4th 2025

Panelists discuss how early-stage CTCL is defined using TNMB staging criteria, the typical presentation of patients at various stages, and the implications for treatment approaches.

Cutaneous T-Cell Lymphoma Insights: Distinguishing MF and SS, and Recognizing Early-Stage Clues

June 4th 2025

Panelists discuss how CTCL is diagnosed, distinguished between mycosis fungoides and Sézary syndrome, and why early-stage disease is often misdiagnosed due to its resemblance to benign skin conditions.

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

May 21st 2025

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

Dr Zonder on the Importance of Early Screening for Myeloma Among High-Risk Patients

April 18th 2025

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Dr Zonder on the Epidemiology of Multiple Myeloma

April 7th 2025

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.

Dr Zonder on the Need for Increased Awareness in Multiple Myeloma

March 24th 2025

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma

February 20th 2024

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.